Seeking Alpha

Novartis names oncology chief

  • Novartis (NVS -1.3%) appoints Bruno Strigini as President of Novartis Oncology. Mr. Strigini joins the company from Merck, where he was President for Europe/Canada.
Comments (2)
  • greenduke
    , contributor
    Comments (5) | Send Message
    Novartis stock took a hit today because it appeared to have been outplayed by GSK in its swap for GSK oncology. It looked like GSK was getting out of cancer drug development, but they now appear to have traded traditional drug approach for the more innovative T-cell extracting and boosting approach via a collaboration with Oxford's Adaptimmune. That makes Novartis look bad.


    However, as Merck has realized, there is immediate potential for drug blocking of newly discovered receptors of proteins that cancer cells produce to inhibit immune response. I would guess that something in GSK's proprietary cancer-fighting compounds has potential for the direct approach, and Bruno Strigini has a good idea how to do that.


    Besides Novartis, in cooperation with U Penn, has the lead in T-cell modification with its chimeric antigen receptor infusion via lentivirus. Novartis is alpha dog in this pack of big pharmas.
    2 Jun, 04:39 PM Reply Like
  • biochemist
    , contributor
    Comments (331) | Send Message
    My understanding is that Bruno Strigini was a senior marketing leader at SGP and then, clearly, at MRK. Not sure what he knows about oncology as neither company would be viewed as a player in the area.
    2 Jun, 06:27 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: